{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"25","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"26","value":"8.1"}]}],"title":"Maximum continuous Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"25","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"26","value":"10.9"}]}],"title":"Cumulative Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Response is defined as a platelet count between 50,000 and 400,000 platelets per microliter.","dispersionType":"Full Range","groups":[{"description":"Matching placebo tablets taken once a day","id":"OG000","title":"Placebo"},{"description":"Eltrombopag 50 mg oral tablets taken once a day (QD)","id":"OG001","title":"Eltrombopag 50 mg QD"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Day 1 through Week 26 on-treatment","title":"Maximum and Total Weeks of Platelet Response","type":"SECONDARY","unitOfMeasure":"Weeks"}